REPL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Replimune Group Inc (REPL) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has faced significant setbacks, including a second FDA rejection of its key drug RP1, widespread analyst downgrades, and a sharp decline in stock price. Additionally, technical indicators and financial performance do not support a positive outlook.
The stock is currently in a bearish trend with the MACD histogram at -0.605, RSI at 18.659 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 2.29, with a resistance level at 7.905. Overall, the technical outlook is negative.
NULL identified. The company has no recent positive developments or catalysts.
FDA issued a second Complete Response Letter for RP1, leading to significant uncertainty about the drug's approval.
Widespread analyst downgrades with price targets reduced to as low as $1-$
Stock price fell 64% following the FDA rejection, hitting an all-time low.
Negative sentiment from both hedge funds and insiders, with no significant trading trends.
Financial performance remains poor, with no revenue growth and negative net income.
In Q3 2026, the company reported no revenue growth (0% YoY), a net income of -$70.93M (up 6.92% YoY), and a decline in EPS to -0.77 (-2.53% YoY). Gross margin remains at 0%. Overall, the financials indicate a lack of growth and profitability.
Analyst sentiment is overwhelmingly negative. Multiple firms, including Wedbush, Leerink, H.C. Wainwright, JPMorgan, Jefferies, and BMO Capital, downgraded the stock following the FDA rejection. Price targets have been slashed to as low as $1-$2, reflecting low confidence in the company's future prospects.
